AUTHORS
Jordan Nunnelee, MD, Yoshito Nishimura, M.D., PhD, MPH2, Richard C. Godby, MD3
AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Background:
Rising drug costs disproportionately affect underinsured patients, who are at increased risk for treatment interruption, non-adherence, and adverse outcomes. In hematologic diseases, where many therapies are long-term or lifelong, medication affordability is a critical determinant of real-world effectiveness and survival. Hematologic conditions are particularly impacted by high drug prices due to reliance on specialty medications. Financial toxicity represents a structural barrier to care that may widen outcome disparities independent of disease biology.
Mark Cuban Cost Plus Drug Company (MCCPDC) has become a resource for providers to prescribe otherwise high-cost medications directly to patients at more affordable prices. While MCCPDC is a drug company itself, providing transparent internal pricing and an integrated supply chain, other resources such as GoodRx and SingleCare contract with established pharmacies to secure discounted prices on similar medications. It is unknown how these alternative drug pricing platforms compare to each other in pricing hematologic therapies, including specialty medications.
Aim:
To compare out-of-pocket drug costs for commonly used hematologic therapies across alternative drug pricing platforms (MCCPDC, GoodRx, and SingleCare).
Methods:
Medications used for hematologic and supportive indications were identified from the MCCPDC website. Drugs demonstrating a ≥90% reduction from the listed retail price were included to focus on therapies with the potential for a clinically meaningful financial impact. Prices were compared with GoodRx and SingleCare using the lowest listed cash price at pharmacies in Minneapolis, Minnesota, selected as a representative large metropolitan market. All prices reflect patient out-of-pocket costs without insurance, and data were extracted in July 2026.
Results:
The following seven drugs were included: aminocaproic acid (500mg tablets, 90 count; retail: $1,866; MCCPDC: $127; GoodRx: $136; SingleCare: $129), deferasirox (generic for Jadenu; 360mg tablets, 90 count; retail: $19,548; MCCPDC: $77; GoodRx: not available; SingleCare: not available), dasatinib (50mg tablets, 60 count; retail: $16,167; MCCPDC: $259; GoodRx: not available; SingleCare (100mg tablets, 30 count): $805), imatinib (400mg tablets, 90 count; retail: $28,972; MCCPDC: $93; GoodRx: $198; SingleCare: $268), posaconazole (100mg tablets, 90 count; retail: $4,929; MCCPDC: $116; GoodRx: $136; SingleCare: $129), tretinoin (10mg capsules, 90 count; retail: $5,595; MCCPDC: $324; GoodRx (70 capsules): $580; SingleCare: $866), and eltrombopag (50mg tablets, 30 count; retail: $10,716; MCCPDC: $155; GoodRx: not available; SingleCare: not available).
Conclusions:
All medications found were >93% less expensive than the retail price using these resources. Some medications, such as imatinib, eltrombopag, and deferasirox were >99% less expensive. Among the platforms and medications analyzed, MCCPDC was the most affordable. Utilization of alternative drug pricing programs was associated with substantial reductions in out-of-pocket costs for essential hematologic therapies across many disease types. Such cost reductions may mitigate financial toxicity, improve treatment adherence, and reduce disparities in access to life-prolonging therapies among underinsured patients. In addition to individual patient benefits, these programs may reduce administrative burden for providers by reducing insurance appeals and prior authorization requirements. Future studies are warranted to investigate patient-level utilization, adherence, and outcomes to quantify the downstream clinical and population-level impact of alternative pricing models.
DISCLOSURES
Jordan Nunnelee, MD: No relevant conflicts of interest to declare.